+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions



The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions



Journal of Pharmacology and Experimental Therapeutics 316(1): 336-348



The accuracy of in vitro inhibition parameters in scaling to in vivo drug-drug interactions (DDI) was examined for over 40 drugs using seven human P450-selective marker activities in pooled human liver microsomes.

(PDF emailed within 0-6 h: $19.90)

Accession: 012687517

Download citation: RISBibTeXText

PMID: 16192315

DOI: 10.1124/jpet.105.093229


Related references

In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clinical Pharmacology and Therapeutics 78(6): 582-592, 2005

In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. Aaps Journal 10(2): 410-424, 2008

A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data. Drug Metabolism and Disposition: the Biological Fate of Chemicals 35(1): 79-85, 2006

Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data. Chemical Research in Toxicology 25(11): 2285-2300, 2013

Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole. Drug Metabolism and Disposition: the Biological Fate of Chemicals 36(7): 1261-1266, 2008

Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole. Drug Metabolism and Disposition: the Biological Fate of Chemicals 36(7): 1255-1260, 2008

Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. Drug Metabolism and Pharmacokinetics 24(6): 500-510, 2010

Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. Pharmaceutical Research 29(7): 1960-1976, 2012

Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: Prediction of in vivo drug-drug interactions. European Journal of Clinical Pharmacology 55(11-12): 843-852, Feb -March, 2000

Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions. Drug Metabolism and Disposition: the Biological Fate of Chemicals 36(6): 1126-1134, 2008

Mechanism-based inhibition of cytochrome P450 in vitro Implications for drug-drug interactions. Drug Metabolism Reviews 35(Supplement 2): 28, 2003

In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 48(6): 637-646, 2017

In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metabolism and Disposition: the Biological Fate of Chemicals 39(4): 703-710, 2011

Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. European Journal of Pharmaceutical Sciences 36(2-3): 175-191, 2008

Drug-Drug Interactions via Mechanism-Based Cytochrome P450 Inactivation: Points to Consider for Risk Assessment from In Vitro Data and Clinical Pharmacologic Evaluation. Current Drug Metabolism 8(5): 449-462, 2007